The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Priority Health to cover FoundationOne genomic profiles

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Priority Health announced it plans to cover the FoundationOne and FoundationOne Heme genomic profiles for patients with cancer developed by Foundation Medicine Inc.

FoundationOne interrogates the entire coding region in 315 genes and select introns in 28 genes commonly altered in solid tumors, according to Foundation Medicine. FoundationOne Heme analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies, sarcomas and select pediatric cancers.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Cancer progress is not reaching everyone. Native Nations must be part of the solution.

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
By Rodney Haring
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account